Canaccord Reiterates Buy Rating on Palvella Therapeutics (PVLA)

June 25, 2026 6:41 AM

Canaccord analyst Whitney Ijem reiterated a Buy rating and $227.00 price target on Palvella Therapeutics (NASDAQ: PVLA).The analyst commented: "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found